SCHEMBL2833710

SCHEMBL2833710

CCCCC#Cc1c(F)cc(F)c(C(=O)O)c1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
MAPT P10636 2/20 0.34
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
APEX1 P27695 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
MMP2 P08253 1/20 0.34
MMP12 P39900 1/20 0.34
TNK2 Q07912 1/20 0.34
PLK1 P53350 1/20 0.34
PLK3 Q9H4B4 1/20 0.34
HMGCR P04035 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835217 0.81 TNK2 (0.36) FFAR1FFAR4MAPTKDM4ELMNA
SCHEMBL2835353 0.77 CYP3A4 (0.42) FFAR1FFAR4MAPTKDM4ELMNA
SCHEMBL5097670 0.77 FFAR1 (0.48) FFAR1FFAR4MAPTKDM4ESMN1; SMN2
SCHEMBL2833910 0.72 RARB (0.44) FFAR1FFAR4MAPTKDM4ELMNA
SCHEMBL4267671 0.72 RARB (0.44) FFAR1FFAR4TDP1MMP2MMP12
SCHEMBL2835387 0.71 HAO1 (0.39) FFAR1FFAR4MMP2MMP12TNK2
SCHEMBL31590952 0.71 HCAR2 (0.43) PLK1PLK3HCAR2RARBRARA
SCHEMBL2835012 0.69 ALDH1A1 (0.45) MAPTKDM4ELMNACYP1A2CYP3A4
SCHEMBL2831444 0.69 FFAR1 (0.46) FFAR1FFAR4MMP2MMP12TNK2
SCHEMBL30669308 0.69 KCNH2 (0.35) HMGCRGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 FFAR1 2223/4885FFAR4 1850/4885MAPT 3532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.